

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Mepolizumab for treating chronic obstructive pulmonary disease with eosinophilic bronchitis ID1237

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • GlaxoSmithKline (mepolizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Allergy UK • Breathing Matters • British Lung Foundation • Muslim Council of Britain • NARA - The Breathing Charity • Quit 4 Life • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Institute of Radiology • British Thoracic Society • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Chest, Heart and Stroke Scotland • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Northern Ireland Chest Heart and Stroke • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AstraZeneca (symbicort, formoterol) • Boehringer Ingelheim (tiotropium) • Chiesi (fostair, formoterol) • GlaxoSmithKline (seretide, salmeterol) • Goldshield (aminophylline) • Hameln (aminophylline) • Merck Sharp & Dolme UK (roflumilast) • Napp Pharmaceuticals (aminophylline) • Novartis (formoterol) • Orion Pharma (formoterol)

Provisional matrix for the proposed technology appraisal mepolizumab for treating chronic obstructive pulmonary disease with eosinophilic bronchitis ID1237 Issue date: September 2017

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • NHS England • NHS Havering CCG • NHS West Suffolk CCG • Welsh Government 	<ul style="list-style-type: none"> • Teva UK (aminophylline) • UCB (aminophylline) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Association for Lung Research • Cochrane Airways Group • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Provisional matrix for the proposed technology appraisal mepolizumab for treating chronic obstructive pulmonary disease with eosinophilic bronchitis ID1237 Issue date: September 2017

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.